CURE.X.CN Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: July 18, 2025
Report Source: 2025 1st Quarter Report
Biocure Technology Inc. Stock Analysis CURE.X.CN
Canada Materials Nano Cap Report: Biocure Technology, Inc. engages in the development and commercialization of biosimilar products. The firm specializes in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. Additionally, the Company is developing biosimilar technologies for cancer treatment. The Company’s products include Interferon Beta, Ranibizumab and PEG-Filgrastim.
Read More Biocure Technology Inc (CURE.X.CN) Chart
Key Statistics of Biocure Technology Inc (CURE.X.CN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
CAD0.04Volume
6000.00P/E Ratio (TTM)
-52 Week Range
Market Cap
540.00KAvg. Volume
6000.00Dividend Yield
-Financial Metrics & Statements of Biocure Technology Inc (CURE.X.CN)
FAQ's for Biocure Technology Inc (CURE.X.CN)
- According to Musaffa’s Shariah screening methodology, Biocure Technology Inc (CURE.X.CN) is currently classified as NOT HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.